One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium

Antonio R Anzueto, D. Tashkin, S. Menjoge, S. Kesten

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Airway medications have not been shown to reduce the loss of lung function in patients with COPD. We explored whether tiotropium 18 μg once daily could slow the rate of decline of lung function over a 1-year period. We performed a post-hoc analysis of data from 921 ambulatory COPD patients participating in two, 1-year, double-blind, tiotropium vs. placebo-controlled trials. Serial spirometry was obtained at baseline (before first dose of study drug), on day 8, at 6 weeks, and at 3, 6, 9 and 12 months after start of the study. Baseline demographics and lung function were comparable. Baseline FEV 1 was 1.01±0.41 (SD) L (39±14% predicted). Mean decline in trough FEV 1 (i.e. FEV 1 23-24 h after prior use of medication) between days 8 and 344 was 58 ml/year in the placebo group and 12 ml/year in the tiotropium group (p=0.005 vs. placebo); and between days 50 and 344 was 59 ml/year in the placebo group and 19 ml/year in the tiotropium group (p=0.036 vs. placebo). Based on a retrospective analysis of 1-year, placebo-controlled clinical trials, tiotropium was associated with a reduced rate of loss of FEV 1. Longer-term trials specifically designed to study this effect are required to confirm this observation.

Original languageEnglish (US)
Pages (from-to)75-81
Number of pages7
JournalPulmonary Pharmacology and Therapeutics
Volume18
Issue number2
DOIs
StatePublished - Apr 2005

Fingerprint

Spirometry
Chronic Obstructive Pulmonary Disease
Placebos
Lung
Controlled Clinical Trials
Tiotropium Bromide
Demography
Pharmaceutical Preparations

Keywords

  • Chronic obstructive pulmonary disease
  • FEV
  • Lung function
  • Spirometry
  • Tiotropium

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Cite this

One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. / Anzueto, Antonio R; Tashkin, D.; Menjoge, S.; Kesten, S.

In: Pulmonary Pharmacology and Therapeutics, Vol. 18, No. 2, 04.2005, p. 75-81.

Research output: Contribution to journalArticle

@article{3fa1d994e4484730bba57f0ad1c76880,
title = "One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium",
abstract = "Airway medications have not been shown to reduce the loss of lung function in patients with COPD. We explored whether tiotropium 18 μg once daily could slow the rate of decline of lung function over a 1-year period. We performed a post-hoc analysis of data from 921 ambulatory COPD patients participating in two, 1-year, double-blind, tiotropium vs. placebo-controlled trials. Serial spirometry was obtained at baseline (before first dose of study drug), on day 8, at 6 weeks, and at 3, 6, 9 and 12 months after start of the study. Baseline demographics and lung function were comparable. Baseline FEV 1 was 1.01±0.41 (SD) L (39±14{\%} predicted). Mean decline in trough FEV 1 (i.e. FEV 1 23-24 h after prior use of medication) between days 8 and 344 was 58 ml/year in the placebo group and 12 ml/year in the tiotropium group (p=0.005 vs. placebo); and between days 50 and 344 was 59 ml/year in the placebo group and 19 ml/year in the tiotropium group (p=0.036 vs. placebo). Based on a retrospective analysis of 1-year, placebo-controlled clinical trials, tiotropium was associated with a reduced rate of loss of FEV 1. Longer-term trials specifically designed to study this effect are required to confirm this observation.",
keywords = "Chronic obstructive pulmonary disease, FEV, Lung function, Spirometry, Tiotropium",
author = "Anzueto, {Antonio R} and D. Tashkin and S. Menjoge and S. Kesten",
year = "2005",
month = "4",
doi = "10.1016/j.pupt.2004.10.003",
language = "English (US)",
volume = "18",
pages = "75--81",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium

AU - Anzueto, Antonio R

AU - Tashkin, D.

AU - Menjoge, S.

AU - Kesten, S.

PY - 2005/4

Y1 - 2005/4

N2 - Airway medications have not been shown to reduce the loss of lung function in patients with COPD. We explored whether tiotropium 18 μg once daily could slow the rate of decline of lung function over a 1-year period. We performed a post-hoc analysis of data from 921 ambulatory COPD patients participating in two, 1-year, double-blind, tiotropium vs. placebo-controlled trials. Serial spirometry was obtained at baseline (before first dose of study drug), on day 8, at 6 weeks, and at 3, 6, 9 and 12 months after start of the study. Baseline demographics and lung function were comparable. Baseline FEV 1 was 1.01±0.41 (SD) L (39±14% predicted). Mean decline in trough FEV 1 (i.e. FEV 1 23-24 h after prior use of medication) between days 8 and 344 was 58 ml/year in the placebo group and 12 ml/year in the tiotropium group (p=0.005 vs. placebo); and between days 50 and 344 was 59 ml/year in the placebo group and 19 ml/year in the tiotropium group (p=0.036 vs. placebo). Based on a retrospective analysis of 1-year, placebo-controlled clinical trials, tiotropium was associated with a reduced rate of loss of FEV 1. Longer-term trials specifically designed to study this effect are required to confirm this observation.

AB - Airway medications have not been shown to reduce the loss of lung function in patients with COPD. We explored whether tiotropium 18 μg once daily could slow the rate of decline of lung function over a 1-year period. We performed a post-hoc analysis of data from 921 ambulatory COPD patients participating in two, 1-year, double-blind, tiotropium vs. placebo-controlled trials. Serial spirometry was obtained at baseline (before first dose of study drug), on day 8, at 6 weeks, and at 3, 6, 9 and 12 months after start of the study. Baseline demographics and lung function were comparable. Baseline FEV 1 was 1.01±0.41 (SD) L (39±14% predicted). Mean decline in trough FEV 1 (i.e. FEV 1 23-24 h after prior use of medication) between days 8 and 344 was 58 ml/year in the placebo group and 12 ml/year in the tiotropium group (p=0.005 vs. placebo); and between days 50 and 344 was 59 ml/year in the placebo group and 19 ml/year in the tiotropium group (p=0.036 vs. placebo). Based on a retrospective analysis of 1-year, placebo-controlled clinical trials, tiotropium was associated with a reduced rate of loss of FEV 1. Longer-term trials specifically designed to study this effect are required to confirm this observation.

KW - Chronic obstructive pulmonary disease

KW - FEV

KW - Lung function

KW - Spirometry

KW - Tiotropium

UR - http://www.scopus.com/inward/record.url?scp=11844265905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844265905&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2004.10.003

DO - 10.1016/j.pupt.2004.10.003

M3 - Article

C2 - 15649848

AN - SCOPUS:11844265905

VL - 18

SP - 75

EP - 81

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 2

ER -